DGAP-News Biotest AG: Biotest treats first COVID-19 patient with trimodulin

Nachrichtenquelle: EQS Group AG
06.10.2020, 12:00  |  125   |   |   

DGAP-News: Biotest AG / Key word(s): Research Update
Biotest AG: Biotest treats first COVID-19 patient with trimodulin

06.10.2020 / 12:00
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Biotest treats first COVID-19 patient with trimodulin

- A clear reduction in mortality and in duration of ventilation support during intensive care stay is expected

- Worldwide unique, innovative plasma protein preparation for treatment of COVID-19 patients

- Expedited approval of trimodulin for COVID-19 intended


Dreieich, 6 October 2020. Biotest announced today that the first patient with severe COVID-19 was treated in Spain with trimodulin in the ESsCOVID (Escape from severe COVID-19) trial. Furthermore has the trial been submitted for approval to the Regulatory Agencies in Russia, Brazil and now also in France.

In this multinational phase II clinical trial, approximately 160 adult patients with severe COVID-19 are planned to be enrolled. These are patients with pneumonia or acute respiratory distress syndrome (ARDS) admitted to hospital due to the severity of their disease. After confirmation of SARS-CoV-2 infection and presence of a strong inflammatory response, the patients will be treated either with trimodulin or with placebo as add-on therapy to standard of care.

The clinical concept of this prospective, double-blind, placebo-controlled phase II trial, was developed according to the expectations of the European Medicines Agency (EMA) after a so-called "Rapid Scientific Advice". Biotest aims for an expedited approval of trimodulin to rapidly respond to the need for novel treatment options for patients with severe COVID-19.

Biotest's development product trimodulin is a worldwide unique, innovative antibody preparation. Trimodulin treatment has already demonstrated promising results in a phase II clinical trial with 160 invasive mechanically ventilated patients suffering from severe community-acquired pneumonia (sCAP) with a strong inflammatory response (CIGMA trial).

Seite 1 von 5
Biotest Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

Diskussion: Biotest .... Turnaround des Jahres 2004
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-News Biotest AG: Biotest treats first COVID-19 patient with trimodulin DGAP-News: Biotest AG / Key word(s): Research Update Biotest AG: Biotest treats first COVID-19 patient with trimodulin 06.10.2020 / 12:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest treats first …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel

Diskussionen zu den Werten

ZeitTitel
05.11.20